David Gandara
@drgandara
Medical Oncologist & clinical-translational researcher in lung cancer. Co-Director-Center for Experimental Therapeutics, UC Davis Comprehensive Cancer Center
Agree @StephenVLiu I also prefer Coke (Coca-Cola)
Agree - more similar than different. Slightly different toxicity profile and may vary at an individual patient level. But no meaningful differences in efficacy in my opinion. But I do think that Coke >>> Pepsi...
Diving beyond EGFR in NSCLC with an excellent session chaired by @SchenkLab, featuring a stellar lineup of talks on KRAS, BRAF, ROS1, MET, RET, and more! With insights from @christinemphmd @drgandara @mihaela_aldea @nievamd @riess_md @OncLive #BTGLung2025 #LCSM #Oncology
our #lungcancer session at MECC New Orleans 2025 with @drgandara @IASLC Karen Kelly @lungoncdoc @JuliaRotow Paul Bunn Subramanian @fred_hirsch @EdgardoSantosMD Megan Daly Erminia Mazarelli #lcsm @mecmededucation
💊 How will the accelerated approval of sunvozertinib shape the treatment landscape for EGFR+ #NSCLC? 🌟 In this new interview, @StephenVLiu, weighs in on the implications of the accelerated approval & what could be on the horizon. ➡️ Watch: buff.ly/LjnPRSp #lcsm
At NOSCM, @JuliaRotow presents provocative data supporting continuation of EGFR TKIs after progressive disease, so-called treatment beyond progression (TBP). I am increasingly a believer. Invariably there are residual sensitive clones which need to be controlled
🔥Off the press: @ASCO #LivingGuidelines for Stage IV Non–Small Cell Lung Cancer Without Driver Alterations: ASCO Living Guideline, Version 2025.1 | 👉🏽 ascopubs.org/doi/10.1200/JC… ✅ Clear algorithm for first and second line options ✅ Review of recent data:…
That feeling when 7+ years of work lands on the front page of @NEJM—and one of the people I respect most, @KoheiShitara , writes the editorial. Honored to share this moment with you, Kohei. Here’s to a decade of friendship, and curing gastric cancer. #Matterhorn @MSKCancerCenter
It’s my great honor to write the editorial for the pivotal MATTERHORN study @NEJM @YJanjigianMD @ASCO More global collaboration is needed to further improve outcomes for our patients with gastric/GEJ cancer.@OncoAlert @oncodaily nejm.org/doi/full/10.10…
📢 Abstract Submission & Registration Are Now Open for #ISLB25! Join the international #liquidbiopsy community in Orlando, Florida, from November 1–3, 2025, for the 7th Annual Congress of Liquid Biopsy. Submit your research: 2025.islb.info/call-for-abstr… Register early to save:…
“What counts in life is not the mere fact that we have lived. It is what difference we have made to the lives of others that will determine the significance of the life we lead” - Nelson Mandela
Sometimes you just have to take a deep breath and move on. Other times you need to ventilate. This is one of those times.
New #JITC letter: Authors response to “Letter to the Editor”: “Tumor mutational burden and survival on immune checkpoint inhibition in >8000 patients across 24 cancer types” bit.ly/4loTbp9 @RyonGraf @drgandara @FoundationATCG
🧬Longitudinal Monitoring of ctDNA for Whole-Course Management in NSCLC Patients LUNGCA prospective multicenter cohort study JNCI: Journal of the National Cancer Institute, 2025 🔍 Background Circulating tumor DNA (ctDNA) is a promising tool for detecting minimal residual…
🫁 How are IMFORTE and DeLLphi-304 changing the standard of care for SCLC? 🌟 In this insightful new interview, @StephenVLiu unpacks the #ASCO25 data and what it means for the treatment landscape. ➡️ Watch now: buff.ly/Hh4YzLi #lcsm #SCLC #ASCO2025
Right fit for this position @StephenVLiu People person, self-motivated, knows what is needed to reach goals. Congratulations! 👏👏👏
Honored and humbled to accept a new role as Division Chief for Hematology & Oncology at Georgetown starting next month. Excited for all that the future holds for @Georgetown @LombardiCancer with the best colleagues one could ask for.
Thanks for sharing @tnewsomdavis Agree, an astounding number of trials in this space. Let's hope that more than a few of them lead to meaningful benefits for our patients @IASLC @ASCO
Delighted to be part of ETOP workshop on T-cell Engagers Summary of DLL3 targeting agents 👉 Incredible number of Tarlatamab studies underway 👉 Competitors coming: Obrixtamig trial portfolio equally active 👉 More agents too: especially MK6070 Exciting prospects
How is EGFR-mutant #NSCLC managed in Brazil? In this episode of #LungCancerConsidered, @clarissamathias moderates a discussion with @HaradaGuilherme and Dr. William N. William in Portuguese on treatment approaches for EGFR+ NSCLC. 🎧 Listen now: bit.ly/VTBport
We are proud to announce that #4oncommunity is now online!!! 4oncommunity.com @FabioPagni1 @NicolaFuscoMD @matteo_fassan @OncoAlert @ChristianRolfo @isliquidbiopsy @PasqualePisapia @Al3ssandroRusso @VGristina @weoncologists @VukovicPetra @KMirza @Dr_Ivanoncologo
Lung-MAP 3.0’s easier genetic screening process means @LungMAP will be even better positioned to enroll a group of patients fully representative of the population of patients with advanced #NSCLC in the U.S. lung-map.org @FNIH_Org @CancerResrch @SWOG @theNCI
So true @steveleeyc Incredibly important issue for physicians and health care systems, but most of all for our patients who are losing this safety net. Unbelievable that this is happening in a democracy based on offering hope and opportunity for so many for long.
Hard to believe how much has changed since this June 25 post in terms of access to cancer care for Californians. This meeting now takes on increased importance with #OBBB national changes to #Medicaid. Will highlight efforts of @AmerMedicalAssn @CMAdocs @ASCO and @ANCO_News
"Coke vs Pepsi"? Osi vs Lazer in MARIPOSA trial looks a lot alike. Matter of preference? @StephenVLiu
Analysis of MARIPOSA @JTOonline comparing 1L lazertinib and osimertinib in #EGFR NSCLC. PFS 18.5m with lazertinib vs 16.6m with osimertinib (HR 0.98), RR 83% vs 85%, DOR 16.6m vs 16.8m, OS HR 1.00 - similar tox (laz more rash, osi more diarrhea). jto.org/article/S1556-…
Every cancer patient deserves a complete diagnosis.